News | December 31, 2025
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Subscribe To Our Newsletter & Stay Updated
